Decreased circulatory erythropoietin in hyperacute phase of myocardial ischemia

International Journal of Cardiology

Volumn 146, Issue 3, 2011, Pages

  Alioglu, Emin ^a   Ercan, Ertugrul ^b   Sonmez Tamer, Gulden ^c   Duman, Can ^c   Turk, Ugur ^a   Tengiz, Istemihan ^a   Tuzun, Nurullah ^a   Saygi, Serkan ^d  

^a Central Hospital Izmir   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d Karsiyaka Devlet Hastanesi   (Turkey)

Author keywords

Apoptosis; Erythropoietin; Ischemia

Indexed keywords

ERYTHROPOIETIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

ACUTE DISEASE; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 78951473195     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.12.184     Document Type: Article

References (32)

1. B.D. Westenbrink, A.A. Voors, W.P. Ruifrok, W.H. van Gilst, and D.J. van Veldhuisen Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond Curr Heart Fail Rep 4 3 2007 127 133
2. M. Buyuklu Heart failure: erythropoietin in treatment of anemia Anadol Kardiyol Derg 7 2007 331 347
3. D. Mocini, T. Leone, M. Tubaro, M. Santini, and M. Penco Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease Curr Med Chem 14 21 2007 2278 2287
4. J.E. Baker Erythropoietin mimics ischemic preconditioning Vascul Pharmacol 42 5-6 2005 233 241
5. C. Moon, M. Krawczyk, and D. Paik Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties J Pharmacol Exp Ther 316 3 2006 999 1005
6. M.A. Bogoyevitch An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection Cardiovasc Res 63 2 2004 208 216
7. L. Calvillo, R. Latini, and J. Kajstura Recombinant human erythropoietin protects the myocardium from ischemia reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci USA 100 2003 4802 4806
8. G.L. Wright, P. Hanlon, K. Amin, C. Steenbergen, E. Murphy, and M.O. Arcasoy Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 9 2004 1031 1033
9. F. Fiordaliso, S. Chimenti, and L. Staszewsky A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury Proc Natl Acad Sci USA 102 2005 2046 2051
10. M. Joyeux-Faure Cellular protection by erythropoietin: new therapeutic implications? J Pharmacol Exp Ther 323 3 2007 759 762
11. P. Ghezzi, and M. Brines Erythropoietin as an antiapoptotic, tissue-protective cytokine Cell Death Differ 11 Suppl 1 2004 37 44
12. G. Heusch, and R. Schulz Features of short-term myocardial hibernation Mol Cell Biochem 186 1998 185 193
13. T. Scarabelli, A. Stephanou, and N. Rayment Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury Circulation 104 2001 253 256
14. Z. Cai, D.J. Manalo, and G. Wei Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury Circulation 108 1 2003 79 85
15. C.J. Parsa, A. Matsumoto, and J. Kim A novel protective effect of erythropoietin in the infarcted heart J Clin Invest 112 2003 999 1007
16. M.L. Brines, P. Ghezzi, and S. Keenan Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury Proc Natl Acad Sci U S A 12; 97 19 2000 10526 10531
17. M. Celik, N. Gokmen, and S. Erbayraktar Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury Proc Natl Acad Sci U S A 99 4 2002 2258 2263 19
18. T. Minamino, and M. Kitakaze New therapeutic application of erythropoietin against ischemic heart diseases J Pharmacol Sci 101 2 2006 179 181
19. N.V. Iyer, L.E. Kotch, and F. Agani Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1a Genes Dev 12 1998 149 162
20. E. Falk, P.K. Shah, and V. Fuster Coronary plaque disruption Circulation 92 3 1995 Aug 1 657 671
21. A. Farb, A.P. Burke, and A.L. Tang Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death Circulation 93 7 1996 1354 1363
22. S. Namiuchi, Y. Kagaya, and J. Ohta High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention J Am Coll Cardiol 45 9 2005 1406 1412
23. N. Paffett-Lugassy, and L.I. Zon Epo-EpoR signaling not required for cardiovascular or neural development Blood 100 2002 2277
24. N.S. Chandel, E. Maltepe, E. Goldwasser, C.E. Mathieu, M.C. Simon, and P.T. Schumacker Mitochondrial reactive oxygen species trigger hypoxia-induced transcription Proc Natl Acad Sci U S A 95 20 1998 11715 11720
25. C.H. Kim, Y.S. Cho, Y.S. Chun, J.W. Park, and M.S. Kim Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol signaling pathway Circ Res 90 2 2002 E25 E33
26. K.G. Shyu, M.T. Wang, and B.W. Wang Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat Cardiovasc Res 54 3 2002 576 583
27. E. Ercan Effects of myocardial ischemia on serum erythropoietin levels during the first six hours of balloon angioplasty J Card Resc 3 2006 46 53
28. P. Veng-Pedersen, J.A. Widness, L.M. Pereira, R.L. Schmidt, and L.S. Lowe A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans Biopharm Drug Dispos 20 1999 217 223
29. W.H. Yoon, S.J. Park, I.C. Kim, and M.G. Lee Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats Res Commun Mol Pathol Pharmacol 96 1997 227 240
30. S.H. Chapel, P. Veng-Pedersen, R.L. Schmidt, and J.A. Widness Receptor-based model accounts for phlbotomy-induced changes in erythropoietin pharmacokinetics Exp Hematol 29 2001 425 431
31. Çiçek D, Tamer L, Pekdemir H, et al. Coronary angioplasty induced oxidative stress and its relation with metoprolol use and plasma homocysteine levels - original investigation (Volume:6 Issue: 4 December 2006).
32. AJ Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150